Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Benboubker, Lotfi; Α. Dimopoulos, Meletios; Dispenzieri, Angela; Catalano, John; R. Belch, Andrew; Cavo, Michèle; Pinto, Antonello; Weisel, Katja; Ludwig, Heinz; J. Bahlis, Nizar; Banos, Anne; Tiab, Mourad; Delforge, Michel; Cavenagh, Jamie; Geraldes, Catarina; Lee, Je‐Jung; Chen, Christine; Oriol, Albert; de la Rubia, Javier; Qiu, Lugui; White, Darrell; Binder, Daniel; Anderson, Kenneth; Fermand, Jean-Paul; Moreau, Philippe; Attal, Michel; Knight, Robert; Chen, Guang; Van Oostendorp, Jason; Jacques, Christian; Ervin‐Haynes, Annette; Avet‐Loiseau, Hervé; Hulin, Cyrille; Façon, Thierry

doi:10.1056/nejmoa1402551

Public

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Published in New England Journal of Medicine • Sep 3, 2014

Authors:

Lotfi Benboubker

Meletios Α. Dimopoulos

Angela Dispenzieri

Abstract

BACKGROUND: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two app...

Subject

Medicine

Lenalidomide

Thalidomide

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!